This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. On October 8, 2020, amid press coverage of an emerging inventorship dispute with the U.S. Licensing structures like this go back at least to World War II, when the U.S.
To allocate COVID-19vaccines, the CDC’s Advisory Committee on Immunization Practices , the National Academies of Sciences, Engineering and Medicine (NASEM), and the WorldHealth Organization (WHO) identified ethical goals for prioritization, such as maximizing benefit and minimizing harm, mitigating health inequities, and reciprocity.
Reenita Das Reenita Das is partner and senior vice president for transformational health at Frost & Sullivan. The year 2020 has been a year unlike any other year in our history. By the end of 2021, about 4 billion COVID-19vaccine doses will be delivered globally.
A range of UN Human Rights Treaty Bodies have further contributed to interpret the human rights implications of private actors’ involvement in health care. 3 ICESCR ) for the full realization of the right to health.
As I previously discussed in October of 2020, Moderna pledged not to enforce its patents against makers of COVID-19vaccines during the pandemic. Then, in 2022, Moderna sued competing vaccine makers Pfizer and BioNTech. Forward-Looking Statements Moderna announced its 2020 pledge in a corporate press release.
By December 2020, the world had astonishingly powerful tools against COVID-19. New mRNA vaccines, underpinned by decades of public investment , had been authorized by global regulators. Finally, Congress failed to fund global vaccine assistance , turning its back on the world. By Zain Rizvi.
On January 22, 2020, we shared news from the CDC that confirmed the United States identified its first infection in the country and authorities began scrambling to prepare. We have watched the United States declare a public health emergency. And we have mourned the loss of those that succumbed to the virus.
It is not yet clear why the EC, which was summoned on 22 and 23 January 2020, decided that it was “too early to declare a PHEIC.” ” It has been arguably a problem of political pressure by the Chinese delegate, as well as of incapacity of the EC’s members.
Since the WorldHealth Organization (WHO) declared the Covid-19 pandemic in March 2020, the rate of reporting of safety data has been unprecedented with the EMA reporting a 93% increase in the volume of adverse event reports reported in 2021 compared to 2020 1. . New advances in technology (e.g.,
The phenomenon of medical mis-information accelerated during the COVID-19 pandemic, normalizing weird anti-science and culminating in the rejection among many U.S. health citizens of the vaccine fast-tracked to address the worst effects of the coronavirus. KFF fielded the study in May and June 2023, finding that most U.S.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content